InteKrin

InteKrin Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on developing and commercializing breakthrough therapies for neuroendocrine, metabolic, and immune diseases. Conditions such as diabetes, metabolic syndrome, and cancer are increasingly in need of new treatment options to provide patients with better therapeutic alternatives and help curb soaring healthcare costs. The company is licensing both early- and late-stage compounds that have the potential to unravel the complex hormonal interplay between metabolism, insulin resistance, and obesity.